Introduction {#S0001}
============

The United States is in the midst of an opioid crisis which has placed even more importance on finding novel ways to minimize the amount of opioids patients need after surgery. Multimodal analgesia involves using two or more non-opioid medications to both minimize pain and minimize opioids after surgery. One component of that is the utilization of local anesthetics for postoperative pain control. It has been shown that using local anesthetics in transversus abdominis plane (TAP) blocks effectively provides analgesia for surgery-associated pain following abdominal surgery.[@CIT0001]--[@CIT0004] Blocks can be performed before or after surgery and provide somatic analgesia for the anterior abdomen while decreasing the potential need for opioid pain medication.[@CIT0005]--[@CIT0007] Our group recently reported both retrospective and prospective studies demonstrating that a group-wide transition from either bupivacaine local infiltration or bupivacaine TAP blocks to TAP blocks with liposomal bupivacaine was associated with lower postoperative pain scores, decreases in perioperative nausea, shorter length of hospitalization, and analgesia up through 72 hrs after surgery.[@CIT0008]--[@CIT0010]

The current study was undertaken to more rigorously test the hypothesis that regional TAP block, using liposomal bupivacaine and bupivacaine reduces perioperative opioid requirements compared to the most common technique, local port-site infiltration using 0.25% bupivacaine.

Methods {#S0002}
=======

After obtaining approval from the University of Minnesota Institutional Review Board (IRB protocol 1508M77443) and registration with clinicaltrials.gov (NCT 02519023), we conducted a single institution, randomized, double-blinded, placebo-controlled study comparing TAP blocks with liposomal bupivacaine and 0.25% bupivacaine to port-site infiltration with 0.25% bupivacaine at a large, metropolitan, teaching hospital. We chose to compare TAP blocks with liposomal bupivacaine and 0.25% bupivacaine to port-site infiltration with 0.25% bupivacaine and not a higher concentration of bupivacaine because previous studies have demonstrated no difference in wound infiltration when using a higher concentration of local anesthetic.[@CIT0011],[@CIT0012] Patient consent was written informed consent and this trial was conducted in accordance with the Declaration of Helsinki. We do not intend to share deidentified participant data. Patients were randomly assigned after obtaining informed consent by a research assistant using a randomization sequence from [[www.random.org]{.ul}](http://www.random.org). Treatment allocation was 1:1 using block allocation. All women undergoing planned hysterectomy using a minimally invasive approach (laparoscopy or robotic-assisted) who were over the age of 18 and had an American Society of Anesthesiologists physical status of I--III were eligible for inclusion. Exclusion criteria included: contradiction to regional anesthesia, history of opioid usage for \>3 weeks of continuous usage prior to surgery, patients with known chronic pain syndrome, and patients with an inability to understand the consent process. Because discharge rate was an endpoint, patients with a planned surgical start time after 5 PM were excluded from participation. All patients were operated on by one of six fellowship-trained gynecologic oncology surgeons. Patients who required conversion of a planned minimally invasive surgery to an open procedure were excluded from analyses. Demographic and medical histories were abstracted from the patients' charts.

Each patient underwent both a TAP procedure prior to initiation of surgery and local infiltration of the port sites at the conclusion of surgery. Patients randomized to the experimental arm underwent bilateral infiltration in the TAP as previously described[@CIT0005] using 10 mL of 0.25% bupivacaine with 1:200,000 epinephrine followed by 10 mL of 1.3% liposomal bupivacaine and 10 mL of saline per side (with the liposomal bupivacaine and saline injected as a 50/50 mixture) on each side. Under ultrasound guidance, a 22-gauge 30° beveled echogenic needle was inserted until the tip pierced the transversus abdominis fascia. There the injectate was deposited between the fascia and the transversus abdominis muscle. The port sites were infiltrated with up to 10 mL of sham treatment (normal saline) at the conclusion of surgery. Patients randomized to the control arm had a sham TAP procedure performed using 30 mL of normal saline per side before surgery and underwent local injections at each port site using 10 mL of 0.25% bupivacaine with 1:200,000 epinephrine per port site prior to extubation.

Both the patient and the treating team (surgeon, anesthesiologist, and nurses) were blinded to the treatment assignment; and medications were repackaged by our investigational pharmacy to precluded incidental identification. There were no alterations in the protocol during the course of this study.

During the surgery and the postoperative care, all opioids were recorded. Pain was assessed using a 10-point numerical scale at 1 and 2 hrs postoperatively by the post-anesthesia unit nurses and at 6, 24, 48, and 72 hrs postoperatively by a research assistant; all assessors were also blinded to treatment allocation. Oxycodone (5 mg oral tablet) was given in the post-anesthesia care unit for a pain score of 5 or greater. Postoperatively, all subjects were instructed to take acetaminophen (1 g every 6 hrs), ibuprofen (800 mg every 8 hrs) scheduled for 72 hrs. They also were instructed to take oxycodone (5--10 mg every 4 hrs) only as needed for pain that rated above 5 on a 10-point numerical scale.

Phone interviews were conducted for patients that were discharged prior to planned assessment points. Medication usage and complications, including respiratory suppression and modality-related complications, were assessed at each time point. All patients were administered a Quality of Recovery-15 (QoR15)[@CIT0013] and the Overall Benefit of Analgesia Score (OBAS)[@CIT0014] instruments to assess their subjective sense of recovery at 72 hrs. Complications and/or readmissions occurring up to postoperative day 17 (2 weeks from the conclusion of planned data acquisition) were recorded.

The primary endpoint was total opioid usage by 72 hrs postoperatively. Secondary endpoints included: postoperative pain scores at 24, 48, and 72 hrs; daily opioid usage, QoR15 score at 72 hrs, OBAS score at 72 hrs, incidence of nausea and emesis within 72 hrs, length of time in recovery, postoperative admission rates, and complication rates.

Sample size was determined using median and range of opioid consumption data from our previous trial, in which patients undergoing TAP procedure with liposomal bupivacaine for hysterectomy used a median of 24.9 mg IV morphine equivalentwith ranges of 0--86.[@CIT0009] Using the methods of Hozo et al to estimate the mean and standard deviation of that group using the median and range, we had an estimate mean of 34 and standard deviation of 24.[@CIT0015] Using an α of 0.05, we determined that 62 patient endpoints (31 in each group) were required to provide a β of 0.8 to detect an effect size of at least 0.8 in opioid usage among patients receiving the experimental arm relative to the control arm. Assuming a dropout rate of 20% and conversion to open at 10%, the study was approved to enroll 80 patients. Due to an increased number of conversions to an open procedure, loss to follow-up and screen fails, approval to enroll to up to 95 was obtained.

Most continuous outcomes were not normally distributed (*P*\<0.05 for Shapiro--Wilk test for normality), therefore comparisons used the Wilcoxon rank sum test. Chi-squared tests were used to compare dichotomous variables. *P*-values for secondary analyses were not adjusted for multiple comparisons. All analyses were completed with R-project Software version 3.3.1.

Results {#S0003}
=======

A total of 87 patients were enrolled between July 2016 through April 2017, 49 in experimental and 38 in control arm. There were 201 patients evaluated with 62 reaching final analysis ([Figure 1](#F0001){ref-type="fig"}). Six patients did not receive the allocated intervention due to a change in surgical plan after allocation. One patient discontinued intervention and seven were lost to follow-up. Eleven patients required a conversion to laparotomy (nine in the experimental and two in the bupivacaine infiltration groups). Twenty-seven patients underwent laparoscopy and 35 patients underwent a robotic-assisted approach. Patient demographics are described in [Table 1](#T0001){ref-type="table"}. The groups were well balanced for relevant risk factors.Table 1DemographicsExperimental median (range) N=31Control median (range) N=31*P*-valueAge years58 (32,77)62 (32,88)0.331BMI kg/m^2^33.1 (20.1,51.5)32.4 (18.4,60.4)0.495Weight kg91.9 (59.8,149.0)80.3 (45.3,154.2)0.360Surgical approach (number)Laparoscopic1512Robotic1619Reason For surgery (number)Endometrial cancer1513Endometrial hyperplasia85Pelvic/uterine mass35Hereditary cancer (ER+ breast cancerc gene \[*BRCA*\])21Cervical dysplasia10Endometrial intraepithelial neoplasia10Cervical cancer03Other14[^1][^2] Figure 1CONSORT flow diagram.

Total opioid use over the 72 hrs following surgery was lower for the experimental group compared to the control group (median of 20.8 mg versus 25 mg IV morphine equivalents respectively, *P*=0.03) ([Table 2](#T0002){ref-type="table"}). Opioid requirements were highest immediately following surgery and lower on postoperative days 2 and 3 for most patients. Notably, five patients (16.1%) assigned to the experimental group were opioid free at 72 hrs all while all patients in the control group required at least some opioid pain medication (*P*=0.062). Non-opioid pain management was similar for both groups, with no significant difference in acetaminophen or ibuprofen use. We examined both acetaminophen and ibuprofen use because while the patients were instructed to take these medications as scheduled and oxycodone as needed we discovered during our data analysis that not every patient took the non-opioid medications as scheduled for the full 72 hrs. Thus, we compared the amount used of each medication by each group to ensure the use of acetaminophen and ibuprofen did not influence the end results. There was a significant reduction in median maximal pain scores among patients allocated to the experimental group versus control on postoperative days 1 and 3 but were similar on postoperative day 2 ([Table 3](#T0003){ref-type="table"}). The total maximal pain score which was the sum of maximal pain scores from day 1 through day 3 was significantly lower in the experimental group vs the control group (8.0 (0,29) vs 13.0 (3,30); *P*=0.022).Table 2Opioid use and presence of nausea and vomitingVariablesExperimental median (range) or N (%)Control median (range) or N (%)*P*-valuePACU opioid use (MME)8.3 (0,36)10.0 (0,40)0.1540--24 hrs opioid use (MME)7.5 (0,55)22.5 (0,90)0.13524--48 hrs opioid use (MME)0 (0,45)7.5 (0,38)0.27148--72 hrs opioid use (MME)0 (0,25)5 (0,34)0.2400--72 hrs opioid us (MME)20.8 (0,66)25.0 (5,72)0.034Opioid-free patients5 (16%)0 (0%)0.062Number of patients with nausea/vomiting10 (32.2%)16 (51.6%)0.198[^3] Table 3Maximum pain scoresTime periodExperimental median (range)Control median (range)*P*-value0--24 hrs3.0 (0,10)5.0 (2,10)0.01824--48 hrs3.0 (0,9)4.0 (0,10)0.21948--72 hrs2.0 (0,10)3.0 (0,10)0.0090--72 hrs8.0 (0,29)13.0 (3,30)0.022[^4]

Global measures of clinical effectiveness were mixed; there were significant differences in the QoR15 scores favoring the experimental group over the control group (median 126 versus 115, *P*=0.02), but no significant difference in the OBAS score (median 2 versus 2, *P*=0.11). Indirect measures of pain management including patient satisfaction and length of PACU or hospital stay were similar between the groups ([Table 4](#T0004){ref-type="table"}).Table 4Postoperative and satisfaction valuesVariablesExperimental median (range) or N (%)Control median (range) or N (%)*P*-valueTotal OBAS2.0 (0,10)3.0 (0,11)0.105Total QoR15126 (79,146)115 (65,136)0.021Satisfaction with pain management30 (96.8%)24 (77.4%)0.058Admitted to hospital same day11 (35.5%)16 (51.6%)0.306Length of time in recovery (hours)3.3 (1,8)3.1 (1,9)0.978[^5]

Complications were rare and not significantly different between the groups. Four patients in the control group had urinary retention versus one in the experimental group. One patient in the control group had constipation and one patient in the experimental group had a postoperative urinary tract infection. The incidence of nausea and/or emesis were similar between the experimental and control groups during the study window (33% vs 53%, *P*=0.19).

The Cohen's d effect size for the primary outcome of 0--72 hrs total opioid equivalents using the nonparametric Kruskal--Wallis test is 0.559 (ie, what would be considered a medium effect size).[@CIT0016]

Discussion {#S0004}
==========

This prospective randomized, double-blinded trial demonstrates that preoperatively applied TAP block with liposomal bupivacaine reduced opioid consumption in the first 72 hrs compared to port-site infiltration with bupivacaine in patients undergoing elective robotic or laparoscopic hysterectomy. Patients in the experimental group reported less pain, required fewer total opioids, had a higher quality of recovery score, and were more likely to be opioid free 72 hrs after surgery compared to the control group. Despite these improvements, patient-assessments of the overall benefit of analgesia score were not significantly different, possibly reflecting the general tolerability of minimally invasive approaches to hysterectomy or the multimodal approach to pain management applied to both study arms.

These data suggest that regional anesthesia may effectively improve postoperative recovery across a spectrum of surgeries, and are consistent with multiple reports suggesting benefit from including regional anesthesia (specifically TAP blocks) in enhanced ﻿recovery after surgery (ERAS) protocols in laparoscopic abdominal procedures.[@CIT0017]--[@CIT0024] Most of these reports compare a pre- and post-intervention cohort, a strategy with multiple inherent biases, but multiple prospective head-to-head comparisons have been reported as well, making some comparisons possible.

Despite multiple studies suggesting the efficacy of ERAS principles, there remains no clear consensus regarding a single "optimal" strategy for perioperative pain management after minimally invasive hysterectomy or the ideal outcome measure. A recent study by Gasanova et al showed the analgesic superiority of liposomal bupivacaine infiltration when compared to bupivacaine TAP blocks for open hysterectomy, finding that patients treated with liposomal bupivacaine infiltration had improved pain scores through 48 hrs and less opioid use through 24 hrs when compared to bupivacaine TAP.[@CIT0025] Similarly, Barron et al compared infiltration with liposomal bupivacaine to bupivacaine in laparoscopic hysterectomy, and found the liposomal bupivacaine group to have superior analgesic results on both postoperative day 2 and day 3 but no difference in opioid use.[@CIT0026] These data combined with our current results and previous study results from our institution suggest that the use of liposomal bupivacaine irrespective of modality provides superior analgesia compared to bupivacaine when used in gynecologic procedures.[@CIT0008],[@CIT0009]

Similar results have been recently reported in the urologic and general surgery literature; Hutchins et al reported a prospective randomized trial that TAP blockade with liposomal bupivacaine provided superior analgesic effect in patients undergoing donor nephrectomy compared to bupivacaine TAP blocks.[@CIT0010] Another study by Fayezizadeh et al compared the use of liposomal bupivacaine TAP blocks to no TAP blocks in abdominal wall reconstruction and again found superior analgesic effects in the liposomal bupivacaine TAP block group.[@CIT0006] Additionally, Stokes et al showed in a retrospective analysis that patients who received liposomal bupivacaine TAP blocks for colorectal surgery had improved pain control compared to those who received bupivacaine TAP blocks.[@CIT0027] All of these studies illustrate what we found in our study that the use of a TAP block with liposomal bupivacaine tends to provide superior analgesia than when either no local anesthetic or bupivacaine is used.

Our group previously reported a prospective trial demonstrating that liposomal bupivacaine provided superior pain control to bupivacaine hydrochloride when used in a TAP block for pain control after robotic hysterectomy.[@CIT0004] The TAP blockade technique was identical to that used in the present study and, reassuringly, the 72 hrs opioid usage was similar to what we observed in the TAP group of the current trial, demonstrating reproducibility of the results. Interestingly, analysis of secondary endpoints in both studies observed the highest pain scores and greatest discrepancy between the experimental and control arms in the first 24 hrs postoperatively. In both studies, we compared liposomal bupivacaine to 0.25% bupivacaine and not 0.5% or 0.75% bupivacaine. This is because previous studies have shown no difference in outcomes with the higher local anesthetic concentrations in either TAP blocks or wound infiltration.[@CIT0011],[@CIT0012],[@CIT0028],[@CIT0029] However, this has not been studied and compared to liposomal bupivacaine as such it is not known if there is a difference in comparing a higher concentration of bupivacaine infiltration to liposomal bupivacaine TAPs. The higher local anesthetic dose in our experimental group could explain the decreased opioid use and decreased pain scores. Thus, future studies should attempt to have a more similar total dose of local anesthetic in both groups to see if that has an impact on pain and opioid use. Gasanova et al did compare 0.5% bupivacaine TAP blocks to liposomal bupivacaine infiltration and still found the liposomal bupivacaine infiltration to be superior to the 0.5% TAP blocks.[@CIT0025]

The strengths of this study include the prospective, randomized, sham-controlled, and blinded design. The balance of known risk factors suggests that the randomization was effective and the central blinding of the medications should preclude incidental observer or reporter bias. The effect size was defined a priori and at a level which was felt to be clinically relevant. The inclusion of multiple surgeons as well as both laparoscopic and robotic-assisted approaches suggests the data can be extrapolated to the most common used minimally invasive approaches. Finally, the study was completed over a relatively short period of time, precluding the potential impact of changes in surgical practice.

Despite these strengths, there are multiple weaknesses which should be considered in analyzing these data. All surgeries were performed by experienced surgeons, but specific strategies, including the number of ports used were not mandated. It is hoped that randomization and blinding would mitigate these differences, but standardization would potentially have assured this. Though the infiltration strategies were specified in the protocol, compliance was not measured; however as both the TAP infusate and local infusate were labeled to preclude identification, it is thought that non-compliance was unlikely to bias our results. Another weakness is that we used between 100 and 125 mg of bupivacaine in the control group site vs 50 mg of bupivacaine and 266 mg of liposomal bupivacaine in the experimental group and this disparity of dosing may have impacted outcomes. Also, the sham TAP procedure may have resulted in unintended pain just from the saline expansion of the TAP space. Finally, as most patients were treated in an outpatient setting, we relied on patient reporting of opioid use. While the accuracy of the reports cannot be confirmed, blinding of both the observer and reporter in this case is thought to decrease potential bias.

In conclusion, our study provides high-level evidence that TAP blockade with liposomal bupivacaine prior to a minimally invasive hysterectomy results in lower opioid usage in the first 72 hrs following surgery, without impairment of the quality of recovery. The procedure adds both time and cost to a patient's perioperative experience relative to local infusion but did not impact their operative time or complication rate. These findings are critical in light of the urgent need to decrease prescription opioids with the ongoing opioid epidemic due to the high risk of addiction with such drugs. Further study will be necessary to optimize both the technique and patient selection to optimize the cost:benefit ratio of using perioperative TAP blocks.
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Implication statement {#S0005}
=====================

This study illustrates the analgesic and patient satisfaction benefit of TAP blocks with liposome bupivacaine when compared to surgeon infiltration with bupivacaine in robotic and laparoscopic hysterectomy procedures.
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[^1]: **Notes:**  Liposomal bupivacaine transversus abdominis plane is experimental. Bupivacaine infiltration is control.

[^2]: **Abbreviations:**BMI, body mass index; ER, estrogen receptor.

[^3]: **Notes:**Liposomal bupivacaine transversus abdominis plane is experimental. Bupivacaine infiltration is control. Opioid use is in morphine milligram equivalents (MME).

[^4]: **Notes:** Liposomal bupivacaine transversus abdominis plane is experimental. Bupivacaine infiltration is control.

[^5]: **Notes:**Liposomal bupivacaine transversus abdominis plane is experimental. Bupivacaine infiltration is control.
